Extracellular Vesicles to Predict Outcomes After Transcatheter Aortic Valve Implantation – a Prospective, Multicenter Cohort Study-Reference-Cited by-同舟云学术

Extracellular Vesicles to Predict Outcomes After Transcatheter Aortic Valve Implantation – a Prospective, Multicenter Cohort Study

Published:2024-05-28 Issue: Volume: Page:
ISSN:1937-5387
Container-title:Journal of Cardiovascular Translational Research
language:en
Short-container-title:J. of Cardiovasc. Trans. Res.

Author:

Wilimski Radosław,Budzianowski Jan,Łomiak Michał,Olasińska-Wiśniewska Anna,Pieniak Katarzyna,Jędrzejczyk Szymon,Domaszk Olaf,Chudzik Magdalena,Filipiak Krzysztof J.,Hiczkiewicz Jarosław,Faron Wojciech,Urbanowicz Tomasz,Jemielity Marek,Grygier Marek,Grabowski Marcin,Kuśmierczyk Mariusz,Rymuza Bartosz,Huczek Zenon,Kochman Janusz,van der Pol Edwin,Nieuwland Rienk,Gąsecka Aleksandra^ORCID

Abstract

Abstract Introduction Transcatheter aortic valve implantation (TAVI) is an established treatment for aortic stenosis (AS) in patients at intermediate and high surgical risk. Circulating extracellular vesicles (EVs) are nanoparticles involved in cardiovascular diseases. We aimed to (i) determine the effect of TAVI on plasma concentrations of five EV subtypes and (ii) evaluate the predictive value of EVs for post-TAVI outcomes. Methods Blood samples were collected 1 day before TAVI and at hospital discharge. Concentrations of EVs were evaluated using flow cytometry. Results Concentration of leukocytes EVs decreased after TAVI, compared to the measurement before (p = 0.008). Among 123 patients discharged from the hospital, 19.5% experienced MACCE during the median of 10.3 months. Increased pre-TAVI concentration of phosphatidylserine-exposing EVs was an independent predictor of MACCE in multivariable analysis (OR 5.313, 95% CI 1.164–24.258, p = 0.031). Conclusions Patients with increased pre-TAVI concentration of procoagulant, PS-exposing EVs have over fivefold higher odds of adverse outcomes. Graphical Abstract

Funder

Polskiego Towarzystwa Kardiologicznego

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s12265-024-10521-x.pdf

Reference38 articles.

1. Nkomo VT, Gardin JM, Skelton TN, Gottdiener JS, Scott CG, Enriquez-Sarano M. Burden of valvular heart diseases: a population-based study. Lancet. 2006;368(9540):1005–11.

2. Iung B, Baron G, Tornos P, Gohlke-Bärwolf C, Butchart EG, Vahanian A. Valvular heart disease in the community: a European experience. Curr Probl Cardiol. 2007;32(11):609–61.

3. Lindman BR, Clavel MA, Mathieu P, Iung B, Lancellotti P, Otto CM, et al. Calcific aortic stenosis. Nat Rev Dis Primers. 2016;2:16006.

4. Ben-Dor I, Pichard AD, Gonzalez MA, Weissman G, Li Y, Goldstein SA, et al. Correlates and causes of death in patients with severe symptomatic aortic stenosis who are not eligible to participate in a clinical trial of transcatheter aortic valve implantation. Circulation. 2010;122(11 Suppl):S37-42.

5. Howard C, Jullian L, Joshi M, Noshirwani A, Bashir M, Harky A. TAVI and the future of aortic valve replacement. J Card Surg. 2019;34(12):1577–90.